Effect on Cellular and Humoral Immune Responses of the AS03 Adjuvant System in an A/H1N1/2009 Influenza Virus Vaccine Administered to Adults during Two Randomized Controlled Trials

The influence of AS03(A), a tocopherol oil-in-water emulsion-based adjuvant system, on humoral and cell-mediated responses to A/California/7/2009 H1N1 pandemic vaccine was investigated. In two observer-blind studies, a total of 261 healthy adults aged 18 to 60 years were randomized to receive either AS03(A)-adjuvanted H1N1 vaccine containing 3.75 mu g hemagglutinin (HA) or nonadjuvanted H1N1 vaccine containing 15 or 3.75 mu g HA on days 0 and 21. Hemagglutination inhibition (HI) antibody and T-cell responses were analyzed up to day 42. A first dose of AS03(A)-adjuvanted vaccine (3.75 mu g HA) or nonadjuvanted vaccine (15 mu g HA) induced HI responses of similar magnitudes that exceeded licensure criteria (e. g., 94 to 100% with titers of >= 40). A lower response following 3.75 mu g HA without adjuvant was observed (73% with titers of >= 40). Following a second dose, geometric mean HI titers at day 42 were higher for AS03A-adjuvanted vaccine (636 and 637) relative to nonadjuvanted vaccine (341 for 15 mu g HA and 150 for 3.75 mu g HA). Over the 42-day period, the increase in frequency of A/H1N1/2009-specific CD4(+) T cells was significantly higher in the adjuvanted group than in the nonadjuvanted group. There was no evidence of correlation between baseline CD4(+) T-cell frequencies and day 21 HI antibody titers, while there was some correlation (R = 0.35) between day 21 CD4(+) T-cell frequencies and day 42 HI titers. AS03A adjuvant enhanced the humoral and CD4(+) T-cell-mediated responses to A/H1N1/2009 vaccine. Baseline A/H1N1/2009-specific CD4(+) T-cell frequencies did not predict post-dose 1 antibody responses, but there was some correlation between post-dose 1 CD4(+) T-cell frequencies and post-dose 2 antibody responses.